My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 382

    1.

    Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.

    Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA.

    Diabetes Care. 2006 Mar;29(3):595-600.PMID: 16505512 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.

    Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y.

    Hypertension. 2005 Feb;45(2):198-202. Epub 2005 Jan 17.PMID: 15655123 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.

    Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y; LIFE substudy.

    J Hypertens. 2004 Sep;22(9):1805-11.PMID: 15311110 [PubMed - indexed for MEDLINE]Related articles

    4.

    Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.

    Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM; LIFE Study Investigators.

    J Hypertens. 2006 Apr;24(4):775-81.PMID: 16531808 [PubMed - indexed for MEDLINE]Related articles

    5.

    Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.

    Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlöf B, Ibsen H, Devereux RB.

    Am J Hypertens. 2005 Nov;18(11):1430-6.PMID: 16280277 [PubMed - indexed for MEDLINE]Related articles

    6.

    The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.

    Fossum E, Gleim GW, Kjeldsen SE, Kizer JR, Julius S, Devereux RB, Brady WE, Hille DA, Lyle PA, Dahlöf B.

    J Intern Med. 2007 Oct;262(4):439-48.PMID: 17875180 [PubMed - indexed for MEDLINE]Related articles

    7.

    Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.

    Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group.

    Hypertension. 2005 Apr;45(4):580-5.PMID: 15790960 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.

    Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR.

    J Hypertens. 2006 Aug;24(8):1531-9.PMID: 16877955 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.

    Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE (Losartan Intervention for Endpoint Reduction) Study Group.

    JAMA. 2002 Sep 25;288(12):1491-8.PMID: 12243636 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]

    Ibsen H, Pedersen OL, Dahlöf B, Kjeldsen SE, Lindholm LH.

    Ugeskr Laeger. 2003 Jan 27;165(5):456-9. Danish. PMID: 12599843 [PubMed - indexed for MEDLINE]Related articles

    11.

    Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.

    Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, Dahlöf B, Devereux RB.

    Hypertension. 2007 Feb;49(2):311-6. Epub 2006 Dec 18.PMID: 17178978 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.

    Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P.

    Ann Intern Med. 2003 Dec 2;139(11):901-6.PMID: 14644892 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).

    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB; LIFE Study Investigators.

    Circulation. 2009 Apr 14;119(14):1883-91. Epub 2009 Mar 30.PMID: 19332468 [PubMed - indexed for MEDLINE]Related articles

    14.

    A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction.

    Olsen MH, Wachtell K, Borch-Johnsen K, Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB, Ibsen H.

    J Hum Hypertens. 2002 Aug;16(8):591-5.PMID: 12149666 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

    Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.

    J Am Coll Cardiol. 2005 Mar 1;45(5):705-11.PMID: 15734614 [PubMed - indexed for MEDLINE]Related articles

    16.

    [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]

    Ibsen H, Lindholm LH, Pedersen OL, Dahlöf B, Kjeldsen S.

    Ugeskr Laeger. 2003 Jan 27;165(5):459-62. Danish. PMID: 12599844 [PubMed - indexed for MEDLINE]Related articles

    17.

    Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.

    Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B; LIFE Study Investigators.

    Circulation. 2006 Mar 28;113(12):1588-96. Epub 2006 Mar 13.PMID: 16534012 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).

    Gerdts E, Papademetriou V, Palmieri V, Boman K, Björnstad H, Wachtell K, Giles TD, Dahlöf B, Devereux RB; Losartan Intervention For End (LIFE) point reduction in hypertension study.

    Am J Cardiol. 2002 Feb 15;89(4):399-402.PMID: 11835919 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.

    Devereux RB, Dahlöf B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, Helle Berg S, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE Study Group.

    Ann Intern Med. 2003 Aug 5;139(3):169-77.PMID: 12899584 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.

    Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, Dahlöf B; LIFE Study Investigators.

    Hypertension. 2007 Nov;50(5):984-90. Epub 2007 Sep 24.PMID: 17893425 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity